This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL).
The name of the study drugs involved in this study are:
* Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2))
* Standard of care CHOP therapy:
* Cyclophosphamide (a type of alkylating agent)
* Doxorubicin (a type of anthracycline antibiotic)
* Vincristine (a type of vinca alkaloid)
* Prednisone (a type of corticosteroid)
* Standard of care BEAM conditioning regimen for autologous stem cell transplant:
* Carmustine (a type of alkylating agent)
* Etoposide (a type of Topoisomerase II inhibitor)
* Cytarabine (a type of antineoplastic)
* Melphalan (a type of alkylating agent)

Start Date01 Apr 2025

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT05617625

/ SuspendedPhase 2IIT

A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myelodysplastic Syndrome

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder.
The CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.

Start Date01 Mar 2025

Sponsor / Collaborator

Baptist Health South Florida, Inc.

NCT05565105

/ Not yet recruitingPhase 2IIT

A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.

Start Date01 Mar 2025

Sponsor / Collaborator

Baptist Health South Florida, Inc.

100 Clinical Results associated with Melphalan

100 Translational Medicine associated with Melphalan

100 Patents (Medical) associated with Melphalan

9,014

Literatures (Medical) associated with Melphalan

01 Jan 2025·EUROPEAN JOURNAL OF HAEMATOLOGY

Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients

Article

Author: Engelhardt, Monika ; Finke, Jürgen ; Strüßmann, Tim ; Hermes, Philipp ; Duque‐Afonso, Jesús ; Marks, Reinhard ; Ihorst, Gabriele ; Duyster, Justus

ABSTRACT:

High‐dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is widely used in patients with diffuse large B‐cell lymphoma. HDCT/ASCT is associated with increased morbidity in elderly/unfit patients. We retrospectively evaluated the use of reduced intensity conditioning in DLBCL patients. Our study included 146 patients aged 60 years and older treated at our institution between 2005 and 2019; 86 patients received standard intensity conditioning (SI group) with BEAM or TEAM (BCNU or thiotepa, etoposide, cytarabine, melphalan). Sixty patients received reduced intensity high‐dose conditioning (RI group) with BM (BCNU, melphalan, 43.3%), TM (thiotepa, melphalan, 16.7%), BCNU or busulfan thiotepa (38.4%), or bendamustine melphalan (1.7%). Median follow‐up was 62.4 months. We observed comparable toxicities in the SI and RI groups. The cumulative incidence of relapse at 3 years was higher in the RI group (30.8% vs. 23.4%, p = 0.034). There was no difference in nonrelapse mortality (NRM). In univariate analyses, SI vs. RI conditioning resulted in superior progression‐free survival (PFS) (HR 1.80 CI 1.11–2.92, p = 0.017) but not in superior overall survival (OS) (HR 1.48 CI 0.86–2.56, p = 0.152). On multivariate analysis, we observed no difference in PFS (HR 0.74 CI 0.40–1.38, p = 0.345) and a trend toward better OS with RI conditioning (HR 0.45 CI 0.22–0.94, p = 0.032). Age 60–69 versus ≥ 70 years and remission prior to ASCT were the only factors predicting better PFS. Factors associated with better OS were RI conditioning, age 60–69 versus ≥ 70 years, ECOG 0 versus ≥ 1 performance status, bulky disease, and prior lines 1 versus ≥ 2. In conclusion, RI conditioning prior to ASCT may be feasible in elderly patients and led to a comparable outcome when corrected for several significant confounders.

01 Jan 2025·ANNALS OF SURGICAL ONCOLOGY

ASO Author Reflections: Optimizing Line of Therapy with the Melphalan/Hepatic Delivery System for Metastatic Uveal Melanoma

Article

Author: Zager, Jonathan S ; Ghali, Helana ; Dugan, Michelle M

01 Jan 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Single- Versus Triple-Agent Intra-Arterial Chemotherapy for Retinoblastoma

Article

Author: Aldhawi, Abeer ; Zaarour, Christian ; Feng, Zhao Xun ; Gallie, Brenda L ; Kletke, Stephanie N ; Muthusami, Prakash ; Alshahrani, Najah O ; Parra-Farinas, Carmen ; Chau, Kelvin ; Mallipatna, Ashwin ; Alshahrani, Najah O. ; Kletke, Stephanie N. ; Shaikh, Furqan ; Gallie, Brenda L.

PURPOSE:

To compare the ocular and systemic outcomes of single- (melphalan) versus triple-agent (melphalan, topotecan, carboplatin) intra-arterial chemotherapy (IAC) for retinoblastoma (RB) eye salvage.

DESIGN:

Retrospective single-institutional clinical cohort study.

METHODS:

Children <18 years with RB who underwent one or more IAC procedures between 2016 and 2024 with minimum 6-month follow-up were reviewed. Data included clinical features, IAC procedural details, additional eye-saving treatments, complications, and follow-up. Primary outcomes included ocular and systemic complications of IAC, intraocular recurrence, extraocular extension, metastasis, and death. Secondary outcomes were tumor response, ocular survival, and recurrence-free ocular survival. Comparative analysis was performed for single- versus triple-agent groups. A SWIMMER^rb plot graphically illustrated additional treatments following IAC.

RESULTS:

Thirty-eight eyes of 37 children (24 unilateral RB) were reviewed. Two eyes (2 children) had single- followed by multi-agent IAC and were excluded. Of 35 included children, one had bilateral triple-agent IAC. IAC (median, 3 doses; range, 1-4) was employed as primary (n = 21 eyes) or secondary (n = 15 eyes) treatment. Chemotherapy was single-agent in 13 eyes and triple-agent in 23 eyes. Following IAC, 25 eyes required additional eye-saving treatments (69% single- v 70% triple-agent, P = .983). At final follow-up, the triple-agent group was more likely to achieve very good partial or complete tumor response (91% v 62%, P = .030). Two-year recurrence-free ocular survival was 63.3% (95% CI 45.7-80.9), similar for both groups (P = .700). Globe salvage was 72%. Two-year ocular survival was 72.2% (95% CI 57.2-87.2), higher for the triple-agent group (82.6% v 53.8%; P = .059). Ocular complications occurred in 31% of eyes in the single- and 52% of eyes in the triple-agent group (P = .215). The rate of systemic complications was 38% versus 74% in the single- versus triple-agent groups, respectively (P = .036). No extraocular extension, metastasis, or death were observed at median 34.2 months (range, 14.5-87.0) follow-up.

CONCLUSIONS:

Triple-agent IAC was associated with improved RB tumor response and ocular survival, though similar recurrence-free ocular survival compared to single-agent. While there were more complications with triple-agent IAC, most were mild or transient.

119

News (Medical) associated with Melphalan

13 Jan 2025

·www.businesswire.com

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

QUEENSBURY, N.Y.--( BUSINESS WIRE )--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024. Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue expected to be approximately $13.7 million and $32.3 million, respectively CHEMOSAT ® fourth quarter and full year revenue expected to be approximately $1.4 million and $4.9 million, respectively Gross margins expected to be in the 80%-85% range As of December 31, 2024, the Company had approximately $53.2 million of cash, cash equivalents and short-term investments and no debt Final financial results for the fourth quarter and full year 2024 and a detailed business update will be provided during Delcath’s annual financial results release and investor call scheduled for March 6, 2025. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information , including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Preliminary and Unaudited Nature of Reported Results The Company has not yet completed its financial close process for the fourth quarter and full year 2024 and, as a result, actual results may vary from the estimated preliminary results set forth in this press release due to a number of factors, including audit adjustments and other developments that may arise between now and the time the financial results for the fourth quarter and fiscal year ended December 31, 2024, are finalized. The estimated preliminary financial results have not been audited or reviewed by the Company’s independent registered public accounting firm. These estimates should not be viewed as a substitute for the Company’s full interim or annual audited financial statements. Safe Harbor / Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: changes to the estimated preliminary results set forth in this press release as a result of audit adjustments and other developments that may arise between now and the time the financial results for the fourth quarter and fiscal year ended December 31, 2024, are finalized; the Company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company's ability to obtain reimbursement for the HEPZATO KIT; and the Company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Drug ApprovalFinancial Statement

03 Jan 2025

·www.businesswire.com

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--( BUSINESS WIRE )--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual whose employment commenced on November 4, 2024. The grant totaled the right to purchase 30,000 shares of the Company’s common stock and is subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The options were granted on December 31, 2024, the date the Compensation Committee approved the stock option included within the equity inducement and are subject to an exercise price equal to $12.04, the closing price of Delcath’s common stock on December 31, 2024. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term and the vesting of the options is subject to the employee’s continued employment with Delcath on each vesting date. The above-described award was granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan. About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT . In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Drug Approval

30 Dec 2024

·www.businesswire.com

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

QUEENSBURY, N.Y.--( BUSINESS WIRE )--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement, had an exercise price of $10.00 per share and expired on December 24, 2024. “With the exercise of these warrants, current cash on hand and cash expected from operations as a result of our revenue growth, we believe that we are in a strong position to execute on our ongoing commercialization efforts and our robust clinical development plan,” said Gerard Michel, Delcath’s Chief Executive Officer. Mr. Michel continued, “As we continue to drive the commercial success of HEPZATO to treat uveal melanoma patients we can confidently invest in new clinical trials.” About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT ™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information , including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Safe Harbor / Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company’s ability to obtain reimbursement for the HEPZATO KIT; and the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Drug Approval

100 Deals associated with Melphalan

External Link

KEGG	Wiki	ATC	Drug Bank
D00369	Melphalan	L01AA03	DB01042

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Polycythemia Vera	CN	Glaxo Wellcome, Inc.	01 Jan 1998
Retinoblastoma	CN	Glaxo Wellcome, Inc.	01 Jan 1998
Breast Cancer	CA	Apotex, Inc.	01 Jan 1963
Melanoma	CA	Apotex, Inc.	01 Jan 1963
Multiple Myeloma	CA	Apotex, Inc.	01 Jan 1963
Ovarian Cancer	CA	Apotex, Inc.	01 Jan 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	Phase 2	US	Celgene Corp.	22 Jun 2016
Smoldering Multiple Myeloma	Phase 2	ES	Amgen, Inc.	01 May 2015
Smoldering Multiple Myeloma	Phase 2	ES	Celgene Corp.	01 May 2015
Unresectable Melanoma	Phase 2	US	Bristol Myers Squibb Co.	01 Feb 2011
Relapse multiple myeloma	Phase 2	US	Celgene Corp.	01 Aug 2010
Chronic Myelomonocytic Leukemia	Phase 2	CA	Celgene Corp.	01 Jan 2008
Myelodysplastic Syndromes	Phase 2	CA	Celgene Corp.	01 Jan 2008
Bone Marrow Neoplasms	Phase 2	US	Smithkline Beecham Plc	18 Feb 2002
Recurrent Multiple Myeloma	Phase 1	US	Novartis Pharmaceuticals Corp.	10 Jul 2018
Refractory Multiple Myeloma	Phase 1	US	Novartis Pharmaceuticals Corp.	10 Jul 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024 Manual	Not Applicable	Acute Megakaryoblastic Leukemia	59	Busulfan/Cyclophosphamide	zqrosqvtzz(vwqdhqkxiq) = qwvszsgzko jmgnpharux (uhvqnagwyu ) View more	Positive	08 Dec 2024
				Busulfan/Cyclophosphamide+Melphalan	zqrosqvtzz(vwqdhqkxiq) = dlkhuhlhve jmgnpharux (uhvqnagwyu ) View more
NCT02880293 (CTgov)	Not Applicable	Hematologic Neoplasms	44	Mesna+Fludarabine+cyclophosphamide+melphalan+Filgrastim+Tacrolimus+Mycophenolate Mofetil+thiotepa	ibrylqhiug(xnynonfeaa) = rlitccpcwk sqmgzpstns (dwmrldmtta, rrdccnmmqg - tcvdofpxjm) View more	-	06 Dec 2024
MM-746 (SOHO2024)	Not Applicable	Multiple Myeloma	74	MEL140	sdbjnspces(thmnvtlemo) = vdaeuajerc ixzoijplxw (cxdcfjgexp ) View more	Positive	04 Sep 2024
				MEL200	sdbjnspces(thmnvtlemo) = iuhjrcyegp ixzoijplxw (cxdcfjgexp ) View more
NCT00936936 (CTgov)	Phase 2	Testicular Neoplasms \| Germ Cell and Embryonal Neoplasms	64	Bevacizumab (Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT)	kdtbmbyzpp(haoafewkez) = kqzyaurhlp jfgvdoymza (yxbiuylnns, hgoftfyjyv - vfdvmxveal) View more	-	26 Aug 2024
				Mesna+Etoposide+Carboplatin+Melphalan+Ifosfamide+Gemcitabine+Docetaxel (Cohort 2: HD GeM-DMC+ ICE for Refractory GCT)	kdtbmbyzpp(haoafewkez) = cdhokhklfb jfgvdoymza (yxbiuylnns, vqqwywmhmh - nsmocdzovu) View more
NCT02678572 (FOCUS, Pubmed)	Phase 3	Uveal Melanoma	102	Melphalan/Hepatic Delivery System	ceqsfgwxny(lpvpbtzssz) = zahkwblmaa bhokbbmyqb (wlmsrxdlcs, 26.44 - 47.01) View more	Positive	01 Aug 2024
NCT02678572 (FOCUS, ASCO2024) Manual	Phase 3	Uveal Melanoma	129	Melphalan/Hepatic Delivery System	elamnsugxy(oowmriearj) = nmonhjtatv bpuevdvumo (svzpooonsh ) View more	Positive	24 May 2024
				Melphalan/hepatic delivery system (Best Alternative Care)	elamnsugxy(oowmriearj) = rybxrxmifi bpuevdvumo (svzpooonsh ) View more
ASCO2024	Not Applicable	Multiple Myeloma	246	melphalan (Extramedullary multiple myeloma (EMM))	sggufgpsvt(xvbtjwdsbq) = kykqujnwry gyodgnickp (bewbjsnyoq ) View more	Positive	24 May 2024
				melphalan (Multiple myeloma without extramedullary involvement (non-EMM))	sggufgpsvt(xvbtjwdsbq) = qnbvjmdaqr gyodgnickp (bewbjsnyoq ) View more
NCT02700841 (CTgov)	Phase 2	Multiple Myeloma	8	Peripheral Blood Stem Cell Transplantation--CD34 HSCT+melphalan (Arm I (Vaccine, CD34 Transplant, DLI))	fgbqgovkbq(ahlmzeevlg) = jziyqxsnjd kshaloaxjl (pqhawtznne, mereghtqil - eiitxssabo) View more	-	12 Mar 2024
				Tetanus Toxoid Vaccine+melphalan (Arm II (Vaccine, Stem Cell Transplant))	fgbqgovkbq(ahlmzeevlg) = klytkqzadq kshaloaxjl (pqhawtznne, xoaatrcinc - pxwgxhyzvv) View more
NCT02251821 (CTgov)	Phase 2	Primary Myelofibrosis	61	Umbilical Cord Blood Transplantation+Fludarabine Phosphate+Busulfan+cyclophosphamide+Melphalan+Tacrolimus+Ruxolitinib+Mycophenolate Mofetil+Methotrexate	aakekvwten(uooafcypmu) = mlddtqfjsx gsvggketsy (arezrvzxzs, cstypvphuz - pwvxwfnxxb) View more	-	05 Mar 2024
Tandem Meetings ASTCT and CIBMTR2024 Manual	Phase 1	B-Cell Lymphoma \| Multiple Myeloma	27	Bendamustine 160 mg/m2Melphalan	cmnqbqtlsc(hmlpagwxdc) = ojaulvkaal ljyaalmuwt (evmtaztnxp ) View more	Positive	01 Feb 2024
				Bendamustine0 mg/m2Melphalan	cmnqbqtlsc(hmlpagwxdc) = bugfwqxkea ljyaalmuwt (evmtaztnxp ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis